Illumina, Inc. (NASDAQ:ILMN) – Analysts at Cantor Fitzgerald issued their FY2018 earnings estimates for shares of Illumina in a research report issued on Friday. Cantor Fitzgerald analyst B. Brokmeier expects that the life sciences company will post earnings of $4.35 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $170.00 price objective on the stock.

Several other analysts have also recently weighed in on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $187.00 price objective (up previously from $170.00) on shares of Illumina in a research note on Friday, April 14th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective for the company in a research note on Tuesday, April 4th. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $187.82 price objective for the company in a research note on Monday, March 20th. Leerink Swann reiterated a “buy” rating on shares of Illumina in a research note on Wednesday, April 5th. Finally, Bank of America Corporation lifted their price objective on shares of Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $165.02.

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/26/illumina-inc-to-post-fy2018-earnings-of-4-35-per-share-cantor-fitzgerald-forecasts-ilmn.html.

Illumina (NASDAQ:ILMN) opened at 185.28 on Monday. The firm has a market cap of $27.05 billion, a price-to-earnings ratio of 37.50 and a beta of 0.76. Illumina has a 52-week low of $119.37 and a 52-week high of $189.48. The company has a 50-day moving average of $178.46 and a 200 day moving average of $163.46.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million during the quarter, compared to analyst estimates of $590.51 million. During the same quarter in the prior year, the business posted $0.71 earnings per share. The company’s quarterly revenue was up 4.5% compared to the same quarter last year.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares during the last quarter. Jennison Associates LLC raised its stake in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Geode Capital Management LLC raised its stake in Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after buying an additional 107,941 shares during the last quarter. Norges Bank acquired a new stake in Illumina during the fourth quarter worth $140,899,000. Finally, TIAA CREF Investment Management LLC raised its stake in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares during the last quarter. 93.77% of the stock is currently owned by hedge funds and other institutional investors.

In other Illumina news, insider Michel Bouchard sold 246 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $185.00, for a total transaction of $45,510.00. Following the sale, the insider now directly owns 18,893 shares of the company’s stock, valued at approximately $3,495,205. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 1,609 shares of the business’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $187.07, for a total transaction of $300,995.63. Following the sale, the senior vice president now directly owns 10,936 shares in the company, valued at $2,045,797.52. The disclosure for this sale can be found here. Insiders have sold a total of 95,031 shares of company stock worth $17,086,968 over the last three months. Insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.